Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma
- Conditions
- Recurrent Cervical CarcinomaEpidermal Growth Factor ReceptorNimotuzumabProgression-free SurvivalRadiotherapyObjective Response RateOverall Survival
- Interventions
- Combination Product: Combination of nimotuzumab and radiotherapy
- Registration Number
- NCT04664244
- Lead Sponsor
- Lei Li
- Brief Summary
Patients with recurrent or metastatic uterine cervical squamous carcinoma have very poor prognosis. For eligible patients, radiotherapy remains the choice, which has the most effective impact on the survival periods. On the hand, anti-angiogenic therapy has been proved to be promising treatment for recurrent or advanced cervical carcinomas. This study aims to discover the objective response of combination therapy with nimotuzumab (an anti-epidermal growth factor receptor \[EGFR\] IgG1 humanized monoclonal antibody) and radiotherapy in recurrent or metastatic uterine cervical squamous carcinoma in a single-arm, open, phase 2 clinical trial. The primary endpoint is the objective response rate evaluated by imaging methods. The second endpoints are the progression-free survival and overall survival. The treatment toxicity is regarded as one the second endpoint.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 43
- Female aged more than 18 years
- Eastern Cooperative Oncology Group score 0-1
- Pathological confirmed of uterine cervical squamous carcinoma
- An interval of 3 months or more since the fulfilling of last treatment
- At least one measurable lesion defined by Response Evaluation Criteria in Solid Tumors (RECIST) guideline 1.1
- Anticipative survival period of 3 months or more
- Lab testing within reference ranges
- With appropriate contraception
- Provided consents of participating the trial
- With a history of exposure to other antiangiogenic agents
- With other malignancies within past 3 years
- With vital complications
- With uncontrolled hypertension despite of medical treatment
- With brain metastasis
- With addiction to psychiatric medications or with mental disorders
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description All eligible patients Combination of nimotuzumab and radiotherapy All eligible patients enrolled
- Primary Outcome Measures
Name Time Method Objective response rate 1 years The objective response rate includes complete and partial remission
- Secondary Outcome Measures
Name Time Method Adverse event rates 3 years The rates of adverse events judged by Common Terminology Criteria for Adverse Events
Progression-free survival 2 years Progression-free survival from the end of radiotherapy to the disease progression
Overall survival 3 years Overall survival from the start of radiotherapy to the disease progression
Disease control rate 1 year The rates of complete and partial remission, and stable disease
Trial Locations
- Locations (1)
Lei Li
🇨🇳Beijing, Beijing, China